GOVX
GeoVax Labs, Inc. New
Latest price
As of Oct 26, 2026, 7:18 PM EDT · Market data by Massive
Market cap
$1.9M
Volume
227.1K
Previous close
$0.2060
Day range
$0.1896 – $0.2127
Listed
Feb 1, 1995
Coverage
67 articles
Price performance
Recent trading
Newsroom
Latest GOVX coverage
GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System
[ad_1] Manufacturing Process for Phase 3 and Commercial Production Being Developed for GeoVax MVA-Based Vaccines ATLANTA, GA – (NewMediaWire) – March 06, 2024 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced a significant milestone to
GeoVax Reports 2023 Year-End Financial Results and Provides Business Update
[ad_1] Progress across the pipeline in multiple clinical trials, including Phase 2 program of GEO-CM04S1, next-generation Covid-19 vaccine, and multicenter Phase 1/2 study of Gedeptin®, targeting advanced head and neck cancer Catalyst-rich 2024 with data readouts planned throughout the year Company to host conference call and webcast today at 4:30 p.m. E
GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024
[ad_1] GeoVax to Host Conference Call at 4:30 PM ET ATLANTA, GA – (NewMediaWire) – February 22, 2024 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced that it will report 2023 financial results on Thursday, February 29, 2
GeoVax to Present at the 2024 BIO CEO & Investor Conference
[ad_1] ATLANTA, GA – (NewMediaWire) – February 19, 2024 – Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today that its Chairman and CEO, David Dodd, will present at the 2024 BIO CEO & Investor Conference, taking place in-perso
GeoVax Announces Multiple Patent Issuances and Allowances
[ad_1] Intellectual Property Assets Strengthened for Cancer Immunotherapy Program and for Marburg Virus and HIV Vaccines ATLANTA, GA – (NewMediaWire) – February 13, 2024 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced multiple action
GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement
[ad_1] ATLANTA, GA – (NewMediaWire) – January 29, 2024 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that the Company's Board of Directors has approved a reverse stock split of its issued and outstanding shares of common stock, par
GeoVax Announces Gedeptin Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients
[ad_1] Therapy Demonstrated Safety, Stabilization/Shrinkage of Treated Tumors Expanded Development for Monotherapy and Combination Therapy Anticipated ATLANTA, GA – (NewMediaWire) – January 04, 2024 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases,
GeoVax Announces Issuance of Malaria Vaccine Patent
[ad_1] Patent Covers Multiple Component Vaccine for Both Prevention and Treatment ATLANTA, GA – (NewMediaWire) – January 03, 2024 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that the U.S. Patent and Trademark Office has issued
GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox
[ad_1] ATLANTA, GA – (NewMediaWire) – December 19, 2023 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that it has amended a previously executed Patent and Biological Materials License Agreement (the “License Agreement”) with the Na
GeoVax Hemorrhagic Fever Vaccine Data Presented at World Vaccine Congress
[ad_1] 80% Survival in Nonhuman Primates Observed in a Lethal Challenge Model ATLANTA, GA – (NewMediaWire) – November 30, 2023 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the presentation of data from recent preclinical studies o
GeoVax to Participate in Upcoming December Investor Events
[ad_1] ATLANTA, GA – (NewMediaWire) – November 29, 2023 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that its senior management will participate in two upcoming investor events: NobleCon19, December 3-5, 2023, Boca Raton, FL Dat
Progress on GeoVax's Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023
[ad_1] Single-Dose Protection Demonstrated Against Multiple SARS-CoV-2 Variants ATLANTA, GA – (NewMediaWire) – November 14, 2023 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the presentation of preclinical vaccine efficacy data fo
GeoVax to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 8, 2023
[ad_1] GeoVax to Host Conference Call at 4:30 PM ET ATLANTA, GA – (NewMediaWire) – October 31, 2023 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced that it will report third quarter 2023 financial results on Wednesday
GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine
[ad_1] Designed to Protect Immunocompromised Patients Against Severe COVID-19 ATLANTA, GA – (NewMediaWire) – October 30, 2023 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that it has commenced the planned site expansion for the Ph
GeoVax to Participate in Upcoming October Investor and Industry Events
[ad_1] Company to Provide Updates on Phase 2 Clinical Trials for Next Generation COVID-19 Vaccine and Cancer Immunotherapy Programs ATLANTA, GA – (NewMediaWire) – September 27, 2023 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announce
GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX Suspension Cell Line to Bolster MVA-Based Vaccine Development
[ad_1] ATLANTA, GA and BERLIN, Germany – (NewMediaWire) – September 26, 2023 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing vaccines and immunotherapies against infectious diseases and cancers, and ProBioGen announce the signing of a landmark commercial license agreement for ProBioGen's groundbreaking AGE1.CR.pIX® su
GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference
[ad_1] Preclinical Data for GEO-CM02 Demonstrates Single-Dose Protection Against Multiple SARS-CoV-2 Variants ATLANTA, GA – (NewMediaWire) – September 20, 2023 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today the presentation of precl
GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference
[ad_1] Updates Presented for Gedeptin® and GEO-CM04S1 Phase 2 Clinical Trials ATLANTA, GA – (NewMediaWire) – September 12, 2023 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that its Chairman and CEO, David Dodd, presented a compa
GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference
[ad_1] Company to Provide Updates on Multiple Phase 2 Clinical Trials for GEO-CM04S1 and Gedeptin® ATLANTA, GA – (NewMediaWire) – August 31, 2023 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that it will present a company overvi
GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia
[ad_1] Seeking Improved Immune Response vs mRNA Vaccine Full Patient Enrollment Expected Within Six Months ATLANTA, GA – (NewMediaWire) – August 10, 2023 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that vaccinations have begun in
GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023
[ad_1] GeoVax to Host Second Quarter 2023 Conference Call at 4:30 PM ET ATLANTA, GA – (NewMediaWire) – July 26, 2023 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, announced today that it will report second quarter 2023 financial resu
GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia
[ad_1] Seeking Improved Immune Response vs mRNA Vaccine ATLANTA, GA – (NewMediaWire) – July 20, 2023 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the start of an investigator-initiated clinical trial (ClinicalTrials.gov Identifi
GeoVax Presents Gedeptin(R) Clinical Data at the AACR-AHNS Head and Neck Cancer Conference
[ad_1] ATLANTA, GA – (NewMediaWire) – July 10, 2023 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today the presentation of Phase 1/2 clinical trial data for GeoVax’s gene therapy candidate, Gedeptin® at the American Association for Canc
GeoVax to Participate in Upcoming Industry Meetings
[ad_1] Management to participate in 2023 ASCO Annual Meeting and 2023 BIO International Convention ATLANTA, GA – (NewMediaWire) – May 25, 2023 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, announced today that its Chief Medical Officer, Kelly T. McKee, M.D
GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update
[ad_1] Cancer Gene Therapy Program and Next-Generation COVID-19 Vaccine Advancing in Phase 2 Clinical Trials Company to Host Conference Call and Webcast Today at 4:30 p.m. ET ATLANTA, GA – (NewMediaWire) – May 04, 2023 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing vaccines and immunotherapies against cancers an
GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate
[ad_1] Analysis of Open-Label Portion of Ongoing Phase 2 Trial of GEO-CM04S1 Presented at 23rd Annual World Vaccine Congress Atlanta, GA – (NewMediaWire) – April 06, 2023 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, presented an update on the dev
GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress
[ad_1] 80% Survival in Nonhuman Primates Observed in a Lethal Challenge Model Atlanta, GA – (NewMediaWire) – April 05, 2023 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the presentation of encouraging data from recent nonhuman pri
GeoVax to Participate at the World Vaccine Congress with Multiple Presentations
[ad_1] New data from the ongoing Phase 2 trial of GEO-CM04S1 to be presented Atlanta, GA – (NewMediaWire) – March 30, 2023 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that it will be represented in two presentations during the
GeoVax Reports 2022 Year-End Financial Results and Provides Corporate Update
[ad_1] Company Expands Ongoing Clinical Trials and the Breadth and Capacity of Its Novel Vaccine Platform Technology ATLANTA, GA – (NewMediaWire) – March 23, 2023 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced its financial result
GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update
[ad_1] Conference call to be held Thursday, March 23, at 4:30 p.m. Eastern Time Atlanta, GA – (NewMediaWire) – March 09, 2023 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, announced today that it will report 2022 financial results on
GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial
[ad_1] Mobile Community Clinical Research Facility to be Deployed in California Atlanta, GA – (NewMediaWire) – February 15, 2023 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, and EmVenio Research, a patient-focused decentralized trial global organ
GeoVax Expands Gedeptin Clinical Research for Advanced Head and Neck Cancers
[ad_1] Phase 1/2 Trial Now Active at Stanford, Emory, and Thomas Jefferson Universities Atlanta, GA – (NewMediaWire) – February 07, 2023 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today its clinical trial of Gedeptin® for patients w
GeoVax to Present at the 2023 BIO CEO & Investor Conference
[ad_1] ATLANTA, GA – (NewMediaWire) – January 26, 2023 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today that its Chairman and CEO, David Dodd, will present at the 2023 BIO CEO & Investor Conference taking place in-person in New York C
GeoVax Receives Notice of Allowance for Zika Vaccine Patent
[ad_1] Preclinical Evaluation Demonstrated 100% Protection Against a Lethal Dose of Zika Virus ATLANTA, GA – (NewMediaWire) – January 25, 2023 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today that the U.S. Patent and Trademark Office
GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023
[ad_1] Atlanta, GA – (NewMediaWire) – January 04, 2023 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today that it will present at the Biotech Showcase coinciding with the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, J
GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update
[ad_1] Phase 2 Clinical Trials Advance for COVID-19 and Immuno-Oncology Company Secures Rights to NIH-MVA for Protection Against Monkeypox and Smallpox ATLANTA, GA – (NewMediaWire) – November 09, 2022 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases
GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate Against Sudan Ebolavirus Showing 100% Protection With a Single Immunization
[ad_1] Atlanta, GA – (NewMediaWire) – July 28, 2022 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer, announced today the publication of a peer-reviewed animal efficacy study of its modified vaccine Ankara (MVA) vectored vaccine against Sudan ebo
GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules
[ad_1] Atlanta, GA – (NewMediaWire) – May 25, 2022 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, announced today that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the issuance and sale of 3,030,304 sh
GeoVax Announces Upcoming Presentations at Scientific Conferences
[ad_1] Atlanta, GA – (NewMediaWire) – May 04, 2022 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer, announced today that it will be represented during presentations at the following upcoming scientific conferences. 2022 National Biotechnol
GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022
[ad_1] Presentation to Focus on GEO-CM02 Being Developed as a Universal Vaccine to Address Evolving SARS-CoV-2 Variants ATLANTA, GA – (NewMediaWire) – March 21, 2022 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, announced today that its Chief Scientific Offi
GeoVax to Participate in Maxim Group's 2022 Virtual Growth Conference
[ad_1] · Chairman & CEO David Dodd to Present Corporate Update · CSO Mark Newman, PhD to Participate in Fireside Chatwith Maxim Analyst Jason McCarthy, PhD Atlanta, GA – (NewMediaWire) – March 16, 2022 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing vaccines and immunotherapies against infectious disea
GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100
[ad_1] Atlanta, GA – (NewMediaWire) – February 22, 2022 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against infectious diseases and cancer, announced today that its Chairman & CEO, David Dodd, has been selected as a 2022 Georgia Titan 100. The Titan 100 program recognizes Georgia’s T
GeoVax Retains CATO SMS to Manage Gedeptin Phase 1/2 Clinical Trial
[ad_1] Activities Underway to Expand and Accelerate Enrollment of Ongoing Study for Head and Neck Cancer Atlanta, GA – (NewMediaWire) – January 13, 2022 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced the engagement of CATO SMS to manage GeoVax
GeoVax Announces $10 Million Private Placement
[ad_1] Atlanta, GA – (NewMediaWire) – January 14, 2022 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, announced today that it has entered into a securities purchase agreement with a single institutional investor to raise approximately $10.0 million through th
GeoVax Issues Shareholder Update Letter
[ad_1] Letter from CEO Describes Achievements during 2021 and Sets Forth New Goals for 2022 Atlanta, GA – (NewMediaWire) – January 04, 2022 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today issued an update letter from Chairman and CEO, David Dodd, to th
GeoVax Reports 2021 Third Quarter Financial Results and Provides Corporate Update
[ad_1] Progress in Clinical Development of COVID-19 and Immuno-Oncology Programs Atlanta, GA – (NewMediaWire) – November 11, 2021 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against infectious diseases and cancers, today announced its financial results for the quarter ended September 3
GeoVax Expands Immuno-Oncology Pipeline with Acquisition of Clinical-Stage Cancer Program
[ad_1] License of Gedeptin® Adds Orphan Drug Clinical Program for Treatment of Advanced Head and Neck Cancers Atlanta, GA – (NewMediaWire) – September 28, 2021 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced that it has ente
GeoVax Presents COVID-19 Vaccine Data at the European Society of Medicine (ESMED) General Assembly
[ad_1] GeoVax Vaccine Being Developed as a Universal Vaccine to Address Evolving SARS-CoV-2 Variants Atlanta, GA – (NewMediaWire) – August 19, 2021 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today presented data from ongoing studies of its preventive vacc
GeoVax to Present at the SNN Network Summer Virtual Event on Wednesday, August 18, 2021
[ad_1] Atlanta, GA – (NewMediaWire) – August 12, 2021 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against infectious diseases and cancers, today announced that it will be presenting at the SNN Network Summer Virtual Event 2021 on Wednesday, August 18, 2021 at 12:30 PM EST. David Dodd,
GeoVax Reports 2021 Second Quarter Financial Results and Provides Corporate Update
[ad_1] Continued Progress on COVID-19 and Immuno-Oncology Programs Atlanta, GA – (NewMediaWire) – August 11, 2021 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against infectious diseases and cancers, today announced its financial results for the quarter ended June 30, 2021. GeoVax’s man
GeoVax to Report Second Quarter 2021 Financial Results on Wednesday, August 11, 2021 and Provide Corporate Update
[ad_1] Conference call to be held Wednesday, August 11, at 4:30 p.m. Eastern Time Atlanta, GA – (NewMediaWire) – August 04, 2021 – GeoVax Labs, Inc. (Nasdaq: GOVX) (“GeoVax” or the “Company”), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, announces today that it will report sec
GeoVax Announces Presentation of Sudan Ebolavirus Vaccine Data at the American Society for Virology Annual Meeting
[ad_1] GeoVax Vaccine Achieves 100% Protection in a Single-Dose Atlanta, GA – (NewMediaWire) – July 22, 2021 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines, today announced the presentation of data from a study of its preventive vaccine against Sudan Ebolavirus (SUDV). The presentation
GeoVax to Participate in the Alliance Global Partners' Virtual Healthcare Symposium
[ad_1] Atlanta, GA – (NewMediaWire) – June 10, 2021 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancers, announced today that it will be participating in the Alliance Global Partners’ Virtual Healthcare Symposium being held on Thursday, June 17, 20
GeoVax to Present to Investors at the Benzinga Global Small Cap Conference on May 13, 2021
[ad_1] GeoVax Chairman & CEO David Dodd to Participate in Panel Discussion Atlanta, GA – (NewMediaWire) – May 06, 2021 – GeoVax Labs, Inc. (NasdaqCM: GOVX), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancers, announced today that management will participate at the Benzinga Global Sm
GeoVax Reports 2021 First Quarter Financial Results and Provides Corporate Update
[ad_1] Additional Capital Raised to Support Acceleration ofCoronavirus and Immuno-Oncology Programs Atlanta, GA – (NewMediaWire) – May 06, 2021 – GeoVax Labs, Inc. (NasdaqCM: GOVX), a biotechnology company developing immunotherapies and vaccines against infectious diseases and cancers, today announced its financial results for the three mo
GeoVax Receives Notice of Allowance for Hepatitis B Vaccine Patent
[ad_1] Therapeutic Vaccine Would Address Medical Need of Over 250 Million Worldwide Atlanta, GA – (NewMediaWire) – April 01, 2021 – GeoVax Labs, Inc. (NasdaqCM: GOVX) (“GeoVax” or the “Company”), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, today announced that the U.S. Patent
GeoVax Reports 2020 Year-End Financial Results And Provides Corporate Update
[ad_1] COVID-19 Vaccine Designed as Single-Dose Against Multiple Strains Immuno-Oncology Programs Advancing Atlanta, GA – (NewMediaWire) – March 23, 2021 – GeoVax Labs, Inc. (NasdaqCM: GOVX), a biotechnology company developing immunotherapies and vaccines against infectious diseases and cancer, today announced its financial results for the
GeoVax Expands and Strengthens Intellectual Property Portfolio
[ad_1] Filings Made in Corporate Focus Areas of SARS-CoV-2 and Immuno-Oncology Atlanta, GA – (NewMediaWire) – March 4, 2021 – GeoVax Labs, Inc. (NasdaqCM: GOVX) (“GeoVax” or the “Company”), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, today announced the filing of two addition
GeoVax Announces Closing of $10.3 Million Bought Deal Offering
[ad_1] Atlanta, GA – (NewMediaWire) – February 11, 2021 – GeoVax Labs, Inc. (NasdaqCM: GOVX) (“GeoVax” or the “Company”), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, today announced the closing of its bought deal offering of 1,644,000 shares of its common stock, which include
GeoVax Announces Pricing of $9.0 Million Bought Deal Offering
[ad_1] Atlanta, GA – (NewMediaWire) – February 8, 2021 – GeoVax Labs, Inc. (Nasdaq: GOVX) (“GeoVax” or the “Company”), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, today announced that it has entered into an underwriting agreement with Maxim Group LLC under
GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development
[ad_1] Company Focused on Single-dose Vaccine Against Multiple COVID Strains Atlanta, GA – (NewMediaWire) – January 11, 2021 – GeoVax Labs, Inc. (NasdaqCM: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today that the National Institute of Allergy and Infectious Dise
GeoVax Announces License Agreement with NIH to Support Continued Advancements in Vaccine Development
[ad_1] Atlanta, GA – (NewMediaWire) – November 30, 2020 – GeoVax Labs, Inc. (NasdaqCM: GOVX, GOVXW) (“GeoVax” or the “Company”), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, today announced the signing of a Patent and Biological Materials License Agreement (the “License Agreem
GeoVax Reports 2020 Third Quarter Financial Results and Provides Corporate Update
[ad_1] Public Offering Completed in September 2020 Provides Resources to Accelerate COVID-19 Vaccine and Immuno-Oncology Programs Atlanta, GA – (NewMediaWire) – November 05, 2020 – GeoVax Labs, Inc. (NasdaqCM: GOVX, GOVXW), a biotechnology company developing immunotherapies and vaccines against infectious diseases and cancers, today announc
GeoVax to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020 and Provide Corporate Update
[ad_1] Conference call to be held Friday, November 6, at 8:15 a.m. Eastern Time Atlanta, GA – (NewMediaWire) – October 30, 2020 – GeoVax Labs, Inc. (NasdaqCM: GOVX, GOVXW) (“GeoVax” or the “Company”), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, announces today that it pl
GeoVax Announces Closing of $12.8 Million Public Offering and Uplisting to Nasdaq
[ad_1] Atlanta, GA – (NewMediaWire) – September 29, 2020 – GeoVax Labs, Inc. (NasdaqCM: GOVX, GOVXW) (“GeoVax” or the “Company”), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, today announced the closing of its underwritten public offering of 2,560,000
GeoVax Announces Pricing of $12.8 Million Public Offering; Uplisting to Nasdaq and Reverse Stock Split
[ad_1] Atlanta, GA – (NewMediaWire) – September 24, 2020 – GeoVax Labs, Inc. (NasdaqCM: GOVX, GOVXW) (“GeoVax” or the “Company”), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, today announced the pricing of its underwritten public offering of 2,560,000 units
GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate Against Marburg Virus Showing 100% Protection
[ad_1] Atlanta, GA – (NewMediaWire) – September 3, 2020 – GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer, announced today the publication of peer-reviewed data of a new vaccine candidate utilizing the company’s GV-MVA-VLP™ platform against Marburg